Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2021 | Story ANDRÉ DAMONS | Photo ANDRÉ DAMONS
Dr Osayande Evbuomwan, a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, always wanted to specialise in an area of medicine that was novel, innovative, intriguing and involved a lot of opportunities for groundbreaking research

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS) always wanted to specialize in an area of medicine that was novel, innovative, intriguing and involved many opportunities for groundbreaking research.

This passionate medical man, who joined the UFS in 2019, is behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer. 
The UFS and the Free State province can now join other South African universities, like the University of Pretoria, University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients. 

Built for this job

Dr Evbuomwan explains nuclear medicine is a medical specialty that involves the use of unsealed sources of radiation in the form of radioisotopes for the diagnosis and treatment of various disease conditions including cancers.
“It’s novelty and opportunity for research and ability to diagnose and treat disease conditions in one specialty attracted me to this field. I always wanted to be a doctor. I see it as a calling. It was also something my mum discovered while I was growing up as a child. In my next life, I would choose to be a medical doctor again,” he says.

“I was built for this job and it is always my joy to have the opportunity to carry out my work. We have been well-trained for this; we support all our skills with prayers. We try to give our patients the very best,” says Dr Evbuomwan, who is originally from Benin City, Edo state, Nigeria. 

After graduating as a nuclear medicine specialist from Wits University, Dr Evbuomwan moved to the City of Roses after a work opportunity opened. He saw it as an opportunity to showcase his talents.

“I have been privileged to receive training in this treatment during my residency training at Wits. I treated a few of these patients during my training and the results were amazing. The University of Pretoria has also been involved with this treatment, with some amazing results that are recognised worldwide. 

“This was enough to convince me to push for our department to also join the powerhouses and offer this treatment to patients who need it. With the influence of a very understanding head of department, Dr Gerrit Engelbrecht, we have been successful in pushing for the commencement of this treatment at our facility,” says Dr Evbuomwan.

Important treatment
According to him, the availability and expertise of Lutetium 177 PSMA (Lu-177 PSMA) therapy to treat MCRPC is very important for the Free State and the UFS, as it is able to offer an option for patients who do not qualify for available conventional treatment and/or who have failed the first line of conventional treatment. 

“In the majority of patients this treatment offers improved quality of life, disease-free progression and improved overall survival. It also alleviates the constant bone pains these patients have to go through daily. To be able to offer this treatment puts the university and the province on the map alongside other top institutions in and outside the country. It also offers opportunity for research,” says Dr Evbuomwan.

He believes with a PET/CT camera for proper staging of these patients with cancer the UFS would be able to expand the treatment of patients suffering from this deadly illness. Currently the university does not possess such a camera and has to use lesser methods in identifying the right patients for this therapy.

News Archive

Protest actions on the Main Campus
2008-03-12

Staff and students are kindly requested to take note of the following protest actions that will take place on the Main Campus.

As a result of a dispute over the status of roads on campus, permission was granted by the municipality and the court, in the presence of the university lawyer for the three actions. Strict conditions have been set for these protest actions.

a.) On Wednesday, 12 March 2008, Satawu and Nehawu will picket in front of the Main Building from 09:00 to 12:00. Three hundred persons will possibly attend this event. Marchers are not allowed within 10 meters from the Main Building and there will be 45 marshals present. This is not a march and no memorandum will be handed over. There may be no speeches.

b.) On Thursday, 13 March Nehawu will again picket in front of the Main Building from 13:00 to 14:00. This event must be peaceful. Only 125 Nehawu members may participate and protesters may not break away from the big group. They may not come within 10 meters of the Main Building. Twenty five of the protesters will be marshals. This is not a march and no memorandum will be handed over. No speeches may be made.

c.) On Friday, 14 March a march of Cosatu and Nehawu will take place. This march will probably be joined by a big number of people.

The march will continue through the Nelson Mandela Gate and will enter the campus grounds, but will be limited to the incoming lane of Chancellors Avenue from the Main Gate to the crossing with Alumni Avenue (in front of the Odeion). Speeches will be made and a memorandum will be handed over.

The march will reach the campus at 10:00 and from then the Nelson Mandela Gate will be closed for all traffic. The march must be finished by 14:00. The marchers will return to the city centre and could cause a traffic problem in Nelson Mandela Avenue.

The South African Police Service and the UFS’s Protection Service will monitor all these actions. Staff are kindly requested to use alternative gates to the Nelson Mandela entrance on Friday. Academic activities continue as normal.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept